mesalamine has been researched along with Leukemia, Monocytic, Acute in 1 studies
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.
Leukemia, Monocytic, Acute: An acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage including monoblasts, promonocytes, and MONOCYTES.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Piccin, A | 1 |
| Cortelazzo, S | 1 |
| Rovigatti, U | 1 |
| Bourke, B | 1 |
| Smith, OP | 1 |
1 other study available for mesalamine and Leukemia, Monocytic, Acute
| Article | Year |
|---|---|
Immunosuppressive treatments in Crohn's disease induce myelodysplasia and leukaemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Budesonide; Chromosomes, Human, Pair 7; | 2010 |